Interagency Coordinating Committee on the Validation of Alternative Methods

Preliminary Agenda

Virtual Meeting

Scientific Advisory Committee on Alternative Toxicological Methods
National Institute of Environmental Health Sciences

10:00 AM – approximately 3:15 PM Eastern Time (meeting may end earlier or later).
Breaks will be taken at the discretion of the chair.

Day 1: Wednesday, November 4, 2026

Time	Agenda Item	Presenter
10:00 AM	**Welcome**	Dr. Sue Marty, The DOW Chemical Company, Chair
	Opening Remarks	Dr. Kyle Walsh, National Institute of Environmental Health Sciences (NIEHS) and National Toxicology Program (NTP) Dr. Nicole Kleinstreuer, Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), National Institutes of Health Office of the Director (NIH OD)
	Introductions	Dr. Marty
	Conflict of Interest (COI) and Housekeeping	Dr. Kelly Chandler, ORIVA, DPCPSI, NIH OD; Designated Federal Officer
	Introduction to NIH Office of Research Innovation, Validation, and Application (ORIVA) ○ Clarifying Questions	Dr. Warren Casey, Executive Director, ICCVAM, ORIVA, DPCPSI, NIH OD
11:05 AM	**Session I: International Harmonization Around Validation**	
	OECD GD34: Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment ○ Clarifying Questions	Dr. João Barroso, European Commission, Joint Research Centre
	OHT 201: OECD Harmonized Template – Intermediate Effects – Mechanistic Information ○ Clarifying Questions	Dr. Ingrid Langezaal, European Commission, Joint Research Centre
	Variability Assessments for Method Development ○ Clarifying Questions	Dr. Martin Paparella, Innsbruck Medical University
12:05 PM	**LUNCH**	
1:05 PM	**Session I: International Harmonization Around Validation (Continued)**	

DRAFT

Interagency Coordinating Committee on the Validation of Alternative Methods

Time	Agenda Item	Presenter
	Overview of Validation Studies Being Supported by NICEATM ○ Clarifying questions	Dr. Helena Hoegberg, Acting Director NICEATM, on Detail to ORIVA, DPCPSI, NIH OD
	Public Comments	Dr. Naomi Charalambakis, Americans for Medical Progress
	SACATM Discussion	Dr. Antonio Baines, North Carolina Central University Dr. Kristini Miles, Miles Consulting, LLC
2:10 PM	**Session II: Federal Efforts Addressing Method Development Challenges**	
	Optimizing the Method Development Pipeline to Accelerate End User Adoption ○ Clarifying Questions	Ms. Amber Daniel, General Dynamics Information Technology (GDIT)
	Lessons Learned from the Complement-ARIE Program – Federal Perspective ○ Clarifying Questions	Dr. Margaret Ochocinska, on Detail to ORIVA, DPCPSI, NIH OD
	Challenges encountered by the VQN around validation – FNIH Perspective ○ Clarifying Questions	Mr. Nicholas King, Foundation for the National Institutes of Health
	Public Comments	Ms. Emily Lasher, Health and Toxics Policy Lab, Stanford University School of Medicine Ms. Kristie Sullivan, Institute for In Vitro Sciences (IIVS) Ms. Sue Leary, Alternatives Research & Development Foundation
	SACATM Discussion	Dr. Gina Hilton, PETA Science Consortium International e.V. Dr. Kambez Benam, University of Pittsburgh
3:45 PM	**ADJOURN Day 1**	Dr. Marty

DRAFT

Interagency Coordinating Committee on the Validation of Alternative Methods

Preliminary Agenda | Virtual Meeting

Scientific Advisory Committee on Alternative Toxicological Methods
National Institute of Environmental Health Sciences

10:00 AM – approximately 3:15 PM Eastern Time (meeting may end earlier or later).
Breaks will be taken at the discretion of the chair.

Day 2: Thursday, November 5, 2026

Time	Agenda Item	Presenter
10:00 AM	**Introductions Day 2**	Dr. Marty
	COI and Housekeeping	Dr. Chandler
10:10 AM	**Session III: IATA Case Studies**	
	OECD IATA Frameworks Program ○ Clarifying questions	Dr. Patience Browne, Organization for Economic Co-operation and Development (OECD)
	Systemic Toxicity IATA Case Studies Project ○ Clarifying questions	Ms. Sullivan, IIVS
	Respiratory Sensitization IATA Case Studies Project ○ Clarifying questions	Dr. Ashley Peppriell, U.S. Environmental Protection Agency
	Progressing Towards a Defined Approach for Developmental Neurotoxicity ○ Clarifying questions	Dr. Anna Kreutz, Applied Research Associates (ARA) Dr. Mary Jacketti, ARA
	Public Comments	Ms. Vicki Katrinak, Humane World for Animals Dr. Shagun Krishna, Physicians Committee for Responsible Medicine (PCRM)
	SACATM Discussion	Dr. Patricia Silveyra, Indiana University Bloomington Dr. Corie Ellison, Procter and Gamble Dr. Nathan Price, Buck Institute for Research on Aging
12:15 PM	**LUNCH**	
1:15 PM	**Session IV: Computational Tools and Databases**	
	CAMERA v2.0: Enhancing Functionality and Test Method Discovery Through Improved Search and Visualization ○ Clarifying Questions	Dr. Katie Needham, Dynanet
	NICEATM Computational Efforts Update: from curated data to interoperable tools ○ Clarifying Questions	Dr. Kamel Mansouri, on Detail to ORIVA, DPCPSI, NIH OD

DRAFT

Interagency Coordinating Committee on the Validation of Alternative Methods

Time	Agenda Item	Presenter
	SARA-NESIL: WOE update ○ Clarifying Questions	Dr. Emily Reinke, GDIT
	Public Comments	Ms. Sullivan, IIVS Dr. Krishna, PCRM
	SACATM Discussion	Dr. Sally Thompson-Irritani, University of Washington Dr. Ellen Berg, Alto Predict LLC Dr. Adrian Nanez, Exelixis, Inc
3:00 PM	**Other Business**	Dr. Chandler
3:10 PM	**ADJOURN Day 2**	Dr. Marty

Next Meeting: SACATM members will be contacted to schedule 2027 meeting.

DRAFT